ELI LILLY & Co (LLY) operating KPIs
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cOVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 0 | -100.0% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 2,020 | -9.8% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 2,240 | +157.1% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 871 | – | Form 10-K (filed 2023-02-22) ↗ |
Breakdown
What makes up covid-19 antibodies (bamlanivimab / etesevimab / bebtelovimab) — worldwide revenue ($m) [legacy separate disclosure]
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy]0 · FY2024
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Outside U.S. revenue ($M) [legacy]0 · FY2024
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy]-100.0% · FY2023
Cite this data
StockData. (2026). Eli Lilly COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M), annual FY2020–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_covid19antibodies_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.